Navigation Links
FDA Approves Xarelto to Prevent Stroke in People With Common Type of Abnormal Heart Rhythm
Date:11/4/2011

taken one time a day with the evening meal so that it will be completely absorbed.  

As with other anti-clotting drugs, Xarelto can cause bleeding that, rarely, can lead to death. Bleeding was the most common adverse event reported by patients treated with Xarelto in the major clinical trial for the prevention of stroke in non-valvular atrial fibrillation. In that trial, Xarelto's risk of major bleeding was similar to that of warfarin; however, it caused less bleeding into the brain and more bleeding into the stomach and intestines.

Xarelto has a boxed warning to make clear that people using the drug should not discontinue it before talking with their health care professional. Discontinuing the drug can increase the risk of stroke.

An FDA-required Medication Guide, which will be given to patients and caregivers when Xarelto is dispensed, describes the risks and adverse reactions people should be mindful of when using the drug.

Xarelto is marketed in the United States by Titusville, N.J.- based Janssen Pharmaceuticals Inc.

On July 1, 2011, the FDA approved Xarelto to reduce the risk of blood clots, deep vein thrombosis, and pulmonary embolism following knee or hip replacement surgery.

For information:
FDA: Approved Drugs: Questions and Answers

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Sandy Walsh, 301-796-4669, sandy.walsh@fda.hhs.gov<
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014 Stryker brand ambassadors ... week at the 3M Championship Champions Tour event near ... in Blaine . Stryker is the official joint ... Starting Friday, August 1 st through Sunday, August ... Mobility Zone; an on-site joint health destination located in the Pioneer ...
(Date:7/30/2014)... , July 30, 2014 Silicon Valley Bank, ... a study today that examines the merger, acquisition ... device companies.  According to the annual report based on ... potential returns since SVB started tracking the data in ... IPO.  Built on solid healthcare M&A activity over the ...
(Date:7/30/2014)... YORK , July 30, 2014 ACCESS ... for oncology supportive care, announced that its novel product ... in an article on OncLive.com titled, "Study Finds Mouth ... Cancers."  Dr. Steve Sonis , a leading expert ... seen in the oncology community for evidence-based strategies for ...
Breaking Medicine Technology:Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3
... the global leader in technology support and BPO services ... today the opening of its new Global Operations Center ... city of Dalian, will specialize in providing services in ... sponsors and clinical research organizations. With dramatic ...
... ARBOR, Mich., April 7, 2011 Adeona Pharmaceuticals, Inc. (AMEX: ... serious central nervous system diseases, announced today that it has ... its common stock at approximately $2.0725 per share to a ... million in gross proceeds. The investor will also receive warrants ...
Cached Medicine Technology:C3i Opens Asia Language Center in Dalian, China 2Adeona to Raise $3.5 Million in Registered Direct Offering 2Adeona to Raise $3.5 Million in Registered Direct Offering 3
(Date:7/30/2014)... 30, 2014 Decene is an ... chain of ten carbon atoms with one double ... of 1-decenes. It can be used as a ... to produce epoxides, amines, oxo alcohols, synthetic lubricants, ... Early buyers will receive 10% customization on this ...
(Date:7/30/2014)... Washington, D.C. (PRWEB) July 30, 2014 ... Community Anti-Drug Coalitions of America (CADCA) , the ... statement in response to the New York Times ... published on Sunday, July 27th. , “CADCA is ... their very public call for national marijuana legalization. The ...
(Date:7/30/2014)... Washington, DC (PRWEB) July 30, 2014 ... have recently joined the Board of Directors of ... provides guidance for the Association, which has a ... in healthcare delivery through telecommunications and information technology. ... members of the Association, possess extraordinary expertise and ...
(Date:7/30/2014)... WEDNESDAY, July 30, 2014 (HealthDay News) -- Medical costs ... States are more than $32 billion each year, according ... Control and Prevention. The yearly financial toll of ... to reach an estimated $49 billion by 2020. ... for COPD, which provide state public health practitioners with ...
(Date:7/30/2014)... whether a person is at risk for suicide could lie ... Chemical changes to a gene involved in the brain,s response ... the study,s authors explained. Spotting those changes in a blood ... suicide, they said. "Suicide is a major preventable public ... efforts because we have no consistent way to predict those ...
Breaking Medicine News(10 mins):Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 2Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 3Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 4Health News:CADCA Responds to New York Times Editorial Board's Call for Marijuana Legalization 2Health News:American Telemedicine Association Welcomes Two New Members to the Board of Directors 2Health News:Annual COPD Costs To Hit $49 Billion by 2020: CDC 2Health News:Could a Blood Test Predict Suicide Risk? 2Health News:Could a Blood Test Predict Suicide Risk? 3
... , , , ... month that the first recipients enrolled in Medicare. Now is the time ... for all," said Dr. Jane L. Delgado, President and CEO of the National ... , , "President Obama set out in his ...
... Evidence That Criticisms Are Registering As Debate Intensifies , ... Congress works through specific health reform proposals, the July Kaiser Health Tracking Poll ... reform now, though there is some softening of support as criticisms and doubts ... been the case over the past ten months, a majority of the American ...
... 28th Annual KLOS Blood Drive Aims ... LOS ANGELES, July 22 The American Red Cross and 95.5 KLOS ... Blood Drive. The 2009 KLOS Blood Drive will run for five days, ... and classic rock fans are encouraged to donate at any of the 19 ...
... , INCLINE VILLAGE, Nev., July 22 PDL BioPharma, ... hold a conference call and webcast on Thursday, July 30 at 4:30 p.m. ... and provide a business update. The call and webcast will follow the release ... , , Conference Call Details , ...
... shows devices contain carcinogens, other toxins , WEDNESDAY, ... cigarettes, known as e-cigarettes, has shown that they ... compound used in antifreeze, U.S. health officials said ... cartridges filled with nicotine, flavorings and other chemicals. ...
... WASHINGTON, July 22 There are many provisions in ... care greatly about the freedom to choose their health care. Some of ... * Eliminates Existing Private Insurance Coverage (i.e., Eliminates Your Choice ... But Is Just Fine With You and Your Family) , ...
Cached Medicine News:Health News:Time to Get the Job Done Says Alliance President and CEO 2Health News:Majority of Public Maintains Support for Addressing Health Care Reform Now 2Health News:Majority of Public Maintains Support for Addressing Health Care Reform Now 3Health News:Majority of Public Maintains Support for Addressing Health Care Reform Now 4Health News:Majority of Public Maintains Support for Addressing Health Care Reform Now 5Health News:KLOS & Red Cross Set to Rock SoCal With Massive 5 Day Blood Drive 2Health News:KLOS & Red Cross Set to Rock SoCal With Massive 5 Day Blood Drive 3Health News:PDL BioPharma to Announce Second Quarter 2009 Financial Results and Hold Conference Call July 30, 2009 2Health News:E-Cigarettes Pose a Health Hazard, FDA Warns 2Health News:E-Cigarettes Pose a Health Hazard, FDA Warns 3Health News:Mandate for Health Insurance: Inconvenient Truths About How It Will Affect You and Your Family 2
... COMBO 2 Assay is a second generation ... capture for in vitro qualitative detection and ... The assay uses a family of Gen-Probe's ... Amplification (TMA) and Dual Kinetic Assay (DKA). ...
... is a novel device for the ... gonorrhoeae and Neisseria meningitidis. This ... and is easily transportable as a ... incubate and examine the growth of ...
... NearVision™ CK is the only procedure designed for ... and +3.00 D or presbyopic patients who would ... D and 2.25 D to achieve a myopic ... in their non-dominant eye to temporarily improve near ...
... The CC-7000 is a mid range space ... take a non-contact picture of the corneal endothelium ... the corneal thickness in the central area. The ... 9" monitor, which is supplied with the system., ...
Medicine Products: